While we are eagerly anticipating the start of a new year filled with endless possibilities, the end of the year provides an opportunity to reflect on an exceptional 2023:
Milestones and Announcements
|
VIDA Named to the Inc 5000 List of Fastest Growing Private Companies in the USThis recognition, based on revenue growth from 2019 through 2022, was a proud moment for the VIDA team. |
|
OSIC Cloud, Powered by VIDA's Intelligence Platform, is Rolled OutWe are thrilled to support the bold mission of OSIC as a member, and now as the platform partner. |
|
Polarean and VIDA Partner to Streamline Adoption of Advanced MRI of the LungsWe were proud to announce our partnership with Polarean, the leader in advanced MRI of the lungs. |
|
VIDA is Granted 2 PatentsVIDA's library of intellectual property grew in 2023, with new patents for our topographic MPR (tMPR) invention & airway coordination system. |
|
VIDA Intelligence Platform Gains Functionality & UsersWe released 15 version updates for the Intelligence Platform in 2023--more than one per month! Key new features include the case viewer, bulk upload, & advanced search. The platform is now empowering more than 5,000 trial site users in 43 countries to produce high quality trial data with ease. |
Webinars
We had the pleasure of speaking with 4 industry luminaries in 2023 as part of our webinar series. These conversations were a big hit with clinical trial sponsors and researchers. Click the links below for highlights of these discussions:
|
|
|
|
|
|
|
Tezepelumab and Mucus Plugs in Patients with Moderate-to-Severe Asthma The headline publication of 2023 was undoubtedly this landmark mucus scoring publication in NEJM Evidence. VIDA is proud to have provided the mucus quantification for this study, using our patent-pending mucus workflow to optimize accuracy and efficiency. |
|
Repeatability of Pulmonary Quantitative CT Measurements in COPD From the SPIROMICS group was an excellent paper on the repeatability of digital imaging biomarkers. The paper found excellent reliability of imaging biomarkers, especially when high QC standards are applied. |
Other Notable Research Collaborations
QCT & visual emphysema scores: association with lung function decline from M. Koo, M. Kirby & team - Link - Feb 2023
Our people and our mission caught the eye of the media on several occasions in 2023. Here are a few notable appearances:
The dogs of VIDA were one of our most shared social medial posts. |
☢️ We have over 10 certified imaging technologists on staff to support trial sites. We surprised them with a radiology themed celebration on Rad Tech day. 🎉 |
Weekly happy hour celebrations have been going strong for 3 straight years at VIDA. They serve as a chance to celebrate accomplishments and have some fun together. In this session, we played a game based on VIDA swag.
In the same spirit, here's a toast 🍾 to you. We extend our warmest wishes for the holiday season and a fantastic New Year!
-Your Friends at VIDA